VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology ...

UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. T cells derived from umbilical cord blood possess the natural advantages of low immunogenicity and ...

CHICAGO--(BUSINESS WIRE)--GSL Biotech and VectorBuilder have formed a partnership to create a complete cloning solution, allowing customers to order their entire custom plasmids directly from ...

CHICAGO, October 08, 2025--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered ...

VectorBuilder Biotechnology has secured investor backing for its push to support gene delivery, raising a 410 million Chinese yuan ($57 million) series C financing round to upgrade and expand its R&D ...

VectorBuilder’s proprietary capsid technology will allow IKAR-003 to be delivered to the eye via the minimally invasive intravitreal route in a doctor’s office. This will enhance access to the ...

Chicago-based VectorBuilder will drop $500 million over the next four years in a two-phase project to build a new gene therapy manufacturing facility and research institute in Guangzhou, China. The ...

VectorBuilder Inc. has announced its plan to invest $30 million to build an ‘AAV Superbank’ for the research and drug discovery community. The company will develop a comprehensive collection of novel ...

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China. VectorBuilder, a global gene delivery solutions company, ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, England & CHICAGO-- ...